Silica Corpora is a company specializing in AI-driven antibody design for therapeutic applications. Founded in 2022 and headquartered in Berlin, Germany, the company develops advanced AI-based platforms to design and optimize therapeutic antibodies targeting priority diseases.

Using their proprietary De Novo antibody therapy platform, Silica Corpora leverages machine learning and data analytics to work exclusively with amino acid sequences to generate quality antibodies with high precision and efficiency.

Their modular system includes several modules such as Generator, Discriminator, Optimizer, and Ep-Mapper that identify and generate novel antibody candidates and predict their properties including developability, thermal stability, solubility, self-aggregation, immunogenicity, and epitope mapping without reliance on 3D structures.

The platform is designed to work with fine-tuned project-specific data, enabling it to find the right solutions efficiently and adapt to existing in vitro workflows without requiring new equipment or personnel.

Silica Corpora's mission is to develop advanced De Novo solutions that deliver enhanced quality and cost-effective antibody therapeutics for diseases with high unmet needs, aiming to transform drug discovery and reduce the costs and time associated with bringing new drugs to market.